Volume: 44 Issue: 3
Comparative Analysis of Once-Weekly Tirzepatide and Once-Daily Insulin Degludec for Diabetes Management: Efficacy, Safety, and Clinical Considerations
Chava Sowmya Devi1, Chennareddy Vijay2, Naga Sai Akhil Reddy Gogula3, Venkata Reddy Gangireddy4, Siva Ranganath Reddy Vaddi5, Ananya Mohapatra6, Annamdevula Vamsi Krishna7, Jonnalagadda Vihari8.
1Research Scholar, M.Sc, CSIR-Indian Institute of Chemical Technology, Hyderabad, Secunderabad, Telangana.(
2Govt. Guntur Medical College, Junior Resident, Guntur, Andhra Pradesh, India.
3Govt. Guntur Medical College, Junior Resident, Guntur, Andhra Pradesh, India.
4Govt. Guntur Medical College, Junior Resident, Guntur, Andhra Pradesh, India.
5Govt. Guntur Medical College, Junior Resident, Guntur, Andhra Pradesh, India.
6Institute of Medical Sciences (IMS) and Sum Hospital, Post Graduate, Siksha 'O' Anusandhan (SOA) Deemed to be University, Department of General Medicine, Bhubaneswar, Odisha.
7Institute of Medical Sciences (IMS) and Sum Hospital, Asst. Professor, Siksha 'O' Anusandhan (SOA) Deemed to be University, Department of General Medicine, Bhubaneswar, Odisha.
8Institute of Medical Sciences (IMS) and Sum Hospital, Siksha 'O' Anusandhan (SOA) Deemed to be University, Department of GastroEnterology, Bhubaneswar, Odisha.
Corresponding Author: Annamdevula Vamsi Krishna Email: [email protected]
Year: 2024,
Page: 254-258,
Doi: https://doi.org/10.51248/v44i3.87
Abstract
In order to control diabetes mellitus, this review article offers a thorough comparison and analysis of once-weekly tirzepatide and once-daily insulin degludec. The review looks at their pharmacokinetics, dosage schedules, and effects on glycemic control and assesses the effectiveness, safety, and tolerability characteristics of these two medicines. We also go over each treatment option's possible benefits and drawbacks, including how each one may affect weight, cardiovascular results, and risk of hypoglycemia. The results of this review are intended to help doctors choose once-weekly tirzepatide or once-daily insulin degludec as their patients' best course of treatment.
Keywords: Tirzepatide, Degludec, Diabetes mellitus, hypoglycemia.
Cite this article
Chava Sowmya Devi, Chennareddy Vijay, Naga Sai Akhil Reddy Gogula, Venkata Reddy Gangireddy, Siva Ranganath Reddy Vaddi, Ananya Mohapatra, Annamdevula Vamsi Krishna, Jonnalagadda Vihari. Comparative Analysis of Once-Weekly Tirzepatide and Once-Daily Insulin Degludec for Diabetes Management: Efficacy, Safety, and Clinical Considerations. Biomedicine: 2024, 44(3): 254-258